Clinical trial · Observational
Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma
Immunophenotype of Peripheral Blood Mononuclear Cells to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma
NCT06777628CI-TRIAL-00084763ImmunecheckrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for: * predicting response to immune-therapeutic regimens in HCC in the early phase of treatment, * to rule out pseudo-progression, * to early predict the escape from effectiveness of treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer, Adult | Malignant Liver Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunochemotherapy combined with antiangiogenic | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- HCC patients
- description
- Patients with advanced HCC undergoing immunotherapy
- interventionNames
- Drug: Immunochemotherapy combined with antiangiogenic
Primary outcomes (1)
- measure
- To find predictive biomarkers of response to immunotherapy in HCC
- timeFrame
- at 3 month
- description
- Sensitivity and specificity of CD8+, PD1+, PD-L1+, CTLA4+, LAG3+, TIGIT+, CD8+PD1+, CD8+PDL1+ peripheral lymphocytes and granulocytes for tumor response prediction according to RECIST 1.1 criteria
Secondary outcomes (1)
- measure
- To compare the transcriptomic signatures of PBMC of responders and non-responders
- timeFrame
- At 3 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age ≥ 18 years * diagnosis of HCC * execution of laboratory tests and subsequent treatments and follow-up at our center. * obtained written informed consent to the study participation Exclusion Criteria: * immune-related concomitant diseases * HIV infection
References
Publications (0)
Data not yet available
No reference posted for this study.